Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurinia Pharmaceuticals (AUPH – Research Report), MAIA Biotechnology, Inc. (MAIA – Research Report) and CG Oncology, Inc. (CGON – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurinia Pharmaceuticals (AUPH)
In a report issued on February 27, David Martin PhD from Bloom Burton maintained a Hold rating on Aurinia Pharmaceuticals, with a price target of $15.00. The company’s shares closed last Friday at $14.17.
PhD has an average return of
According to TipRanks.com, PhD is ranked #743 out of 12142 analysts.
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Moderate Buy with an average price target of $16.00, implying a 14.4% upside from current levels. In a report issued on February 27, TipRanks – xAI also downgraded the stock to Hold with a $15.00 price target.
See the top stocks recommended by analysts >>
MAIA Biotechnology, Inc. (MAIA)
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. today and set a price target of $14.00. The company’s shares closed last Friday at $2.26.
According to TipRanks.com, LeBoyer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MAIA Biotechnology, Inc. with a $14.00 average price target.
CG Oncology, Inc. (CGON)
In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on CG Oncology, Inc., with a price target of $77.00. The company’s shares closed last Friday at $58.80.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CG Oncology, Inc. with a $83.17 average price target, representing a 49.1% upside. In a report issued on February 19, Cantor Fitzgerald also maintained a Buy rating on the stock with a $100.00 price target.
